论文部分内容阅读
医药行业自新中国成立以来便备受重视,政府从行业结构、税收等方面进行宏观调控,其重要性不言而喻。但近几年一些曾经的龙头企业,如北大医药、天目药业等,都面临着退市风险,暗示着部分曾经辉煌的企业内部财务状况、经营状况现阶段十分艰难。企业管理涉及组织结构、流程设计、职责划分、报告等,但管理效率很难直观、数据化反映,由此便需要建立企业财务风险预警体系。近几年医药行业部分上市公司连年亏损,而亏损便是财务风险的直接结果。因而笔者选取部分退市企业与现阶段医药行业龙头企业,从利润表数据中的毛利率、净利率切入对其盈利能力进行了对比分析,提出相应的预警手段。
Since the founding of the pharmaceutical industry in China, it has received much attention. The government’s macro regulation and control over the industrial structure and tax revenue are of paramount importance. However, in recent years, some leading enterprises such as Peking University Pharmaceutical Co., Ltd. and Tianmu Pharmaceutical Co., Ltd. are facing the risk of delisting, implying that some of the once-glorious internal financial positions of enterprises have been in a very difficult situation at present. Business management involves the organizational structure, process design, division of responsibilities, reports, etc., but management efficiency is difficult to visualize, data-based reflection, which will need to establish early warning system for financial risks. In recent years, some listed companies in the pharmaceutical industry have suffered losses year after year, while losses have been the direct result of financial risks. Therefore, the author selects some delisting enterprises and the leading enterprises in the pharmaceutical industry at this stage, and compares their profitability with the gross margin and net interest margin in the income statement data, and puts forward the corresponding warning means.